XML 41 R26.htm IDEA: XBRL DOCUMENT v3.24.0.1
LOSS PER SHARE
 12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
LOSS PER SHARE LOSS PER SHARE
Basic and diluted loss per share attributable to Bausch Health Companies Inc. for 2023, 2022 and 2021 was calculated as follows:
(in millions, except per share amounts)202320222021
Net loss attributable to Bausch Health Companies Inc.$(592)$(225)$(948)
Basic and diluted weighted-average common shares outstanding364.9 362.0 358.9 
Basic and diluted loss per share attributable to Bausch Health Companies Inc.$(1.62)$(0.62)$(2.64)
In 2023, 2022 and 2021, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately 2,719,000, 1,851,000 and 4,932,000 common shares for 2023, 2022 and 2021, respectively.
Additionally, in 2023, 2022 and 2021, stock options, time-based RSUs and performance-based RSUs to purchase approximately 14,461,000, 14,396,000 and 3,428,000 common shares of the Company, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During 2022 and 2021, an additional 156,000 performance-based RSUs were not included in the computation of diluted earnings per share as the required performance conditions had not been met.